AbbVie Inc
For the period ended Dec 31, 2023. Filed Feb 20, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 20, 2024
ABBV$293.89+0.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Income
| years ended December 31 (in millions) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Net earnings | $4,873 | $11,845 | $11,549 |
| Foreign currency translation adjustments, net of tax expense (benefit) of $15 in 2023, $(10) in 2022 and $(35) in 2021 | 407 | (943) | (1,153) |
| Net investment hedging activities, net of tax expense (benefit) of $(109) in 2023, $152 in 2022 and $193 in 2021 | (399) | 555 | 699 |
| Pension and post-employment benefits, net of tax expense (benefit) of $(6) in 2023, $272 in 2022 and $124 in 2021 | (30) | 1,088 | 521 |
| Cash flow hedging activities, net of tax expense (benefit) of $(19) in 2023, $5 in 2022 and $20 in 2021 | (84) | — | 151 |
| Other comprehensive income (loss) | $(106) | $700 | $218 |
| Comprehensive income | 4,767 | 12,545 | 11,767 |
| Comprehensive income attributable to noncontrolling interest | 10 | 9 | 7 |
| Comprehensive income attributable to AbbVie Inc. | $4,757 | $12,536 | $11,760 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.